Literature DB >> 23496671

Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse.

Stephen Brimijoin1, Xiaoyun Shen, Frank Orson, Thomas Kosten.   

Abstract

This review addresses potential new treatments for stimulant drugs of abuse, especially cocaine. Clinical trials of vaccines against cocaine and nicotine have been completed with the generally encouraging result that subjects showing high titers of antidrug antibody experience a reduction in drug reward, which may aid in cessation. New vaccine technologies, including gene transfer of highly optimized monoclonal antibodies, are likely to improve such outcomes further. In the special case of cocaine abuse, a metabolic enzyme is emerging as an alternative or added therapeutic intervention, which would also involve gene transfer. Such approaches still require extensive studies of safety and efficacy, but they may eventually contribute to a robust form of in vivo drug interception that greatly reduces the risks of addiction relapse.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23496671      PMCID: PMC3738206          DOI: 10.1586/erv.13.1

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  91 in total

1.  COMPLETE PSEUDOCHOLINESTERASE DEFICIENCY: GENETIC AND IMMUNOLOGIC CHARACTERIZATION.

Authors:  W HODGKIN; E R GIBLETT; H LEVINE; W BAUER; A G MOTULSKY
Journal:  J Clin Invest       Date:  1965-03       Impact factor: 14.808

2.  AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation.

Authors:  Martin J Hicks; Jonathan B Rosenberg; Bishnu P De; Odelya E Pagovich; Colin N Young; Jian-ping Qiu; Stephen M Kaminsky; Neil R Hackett; Stefan Worgall; Kim D Janda; Robin L Davisson; Ronald G Crystal
Journal:  Sci Transl Med       Date:  2012-06-27       Impact factor: 17.956

3.  Inheritance of two types of deficiency of human serum cholinesterase.

Authors:  E M Scott
Journal:  Ann Hum Genet       Date:  1973-10       Impact factor: 1.670

Review 4.  Immunotherapeutic strategies for cancer treatment: a novel protein transfer approach for cancer vaccine development.

Authors:  Rangaiah Shashidharamurthy; Erica N Bozeman; Jaina Patel; Ramneet Kaur; Jeyandra Meganathan; Periasamy Selvaraj
Journal:  Med Res Rev       Date:  2011-01-16       Impact factor: 12.944

5.  Prophylaxis with human serum butyrylcholinesterase protects guinea pigs exposed to multiple lethal doses of soman or VX.

Authors:  Ashima Saxena; Wei Sun; James M Fedorko; Irwin Koplovitz; Bhupendra P Doctor
Journal:  Biochem Pharmacol       Date:  2010-09-21       Impact factor: 5.858

6.  Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy.

Authors:  Sergey S Seregin; Daniel M Appledorn; Aaron J McBride; Nathaniel J Schuldt; Yasser A Aldhamen; Tyler Voss; Junping Wei; Matthew Bujold; William Nance; Sarah Godbehere; Andrea Amalfitano
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

7.  The effect of a chimeric human/murine anti-cocaine monoclonal antibody on cocaine self-administration in rats.

Authors:  Andrew B Norman; Mantana K Norman; William R Buesing; Michael R Tabet; Vladimir L Tsibulsky; William J Ball
Journal:  J Pharmacol Exp Ther       Date:  2008-12-16       Impact factor: 4.030

8.  Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates.

Authors:  Nicola Brunetti-Pierri; Donna J Palmer; Arthur L Beaudet; K Dee Carey; Milton Finegold; Philip Ng
Journal:  Hum Gene Ther       Date:  2004-01       Impact factor: 5.695

9.  Effects of nicotine infusion on the metabolism of the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in rats.

Authors:  Daniel Keyler; Paul R Pentel; Gwendolyn Kuehl; Greg Collins; Sharon E Murphy
Journal:  Cancer Lett       Date:  2003-12-08       Impact factor: 8.679

10.  Anti-addiction vaccines.

Authors:  Xiaoyun Shen; Frank M Orson; Thomas R Kosten
Journal:  F1000 Med Rep       Date:  2011-10-03
View more
  17 in total

1.  Heroin vaccine: Using titer, affinity, and antinociception as metrics when examining sex and strain differences.

Authors:  Candy S Hwang; Lauren C Smith; Cody J Wenthur; Beverly Ellis; Bin Zhou; Kim D Janda
Journal:  Vaccine       Date:  2019-06-05       Impact factor: 3.641

2.  Heat shock proteins: A dual carrier-adjuvant for an anti-drug vaccine against heroin.

Authors:  Candy S Hwang; Beverly Ellis; Bin Zhou; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2018-11-20       Impact factor: 3.641

Review 3.  Vaccines against drugs of abuse: where are we now?

Authors:  Berma Kinsey
Journal:  Ther Adv Vaccines       Date:  2014-07

Review 4.  Current approaches for the discovery of drugs that deter substance and drug abuse.

Authors:  Adam Yasgar; Anton Simeonov
Journal:  Expert Opin Drug Discov       Date:  2014-09-24       Impact factor: 6.098

Review 5.  Biologics to treat substance use disorders: Current status and new directions.

Authors:  Marco Pravetoni
Journal:  Hum Vaccin Immunother       Date:  2016-07-21       Impact factor: 3.452

Review 6.  Biologic Approaches to Treat Substance-Use Disorders.

Authors:  Phil Skolnick
Journal:  Trends Pharmacol Sci       Date:  2015-10       Impact factor: 14.819

Review 7.  Antagonist models for treating persons with substance use disorders.

Authors:  George E Woody
Journal:  Curr Psychiatry Rep       Date:  2014-10       Impact factor: 5.285

Review 8.  New directions in nicotine vaccine design and use.

Authors:  Paul R Pentel; Mark G LeSage
Journal:  Adv Pharmacol       Date:  2014

9.  Ethical Implications in Vaccine Pharmacotherapy for Treatment and Prevention of Drug of Abuse Dependence.

Authors:  Anna Carfora; Paola Cassandro; Alessandro Feola; Francesco La Sala; Raffaella Petrella; Renata Borriello
Journal:  J Bioeth Inq       Date:  2018-01-19       Impact factor: 1.352

10.  Physiologic and metabolic safety of butyrylcholinesterase gene therapy in mice.

Authors:  Vishakantha Murthy; Yang Gao; Liyi Geng; Nathan K LeBrasseur; Thomas A White; Robin J Parks; Stephen Brimijoin
Journal:  Vaccine       Date:  2014-06-02       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.